Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Edge Therapeutics — Merger or Acquisition (November 2018)
15 slides from Pds Biotechnology's merger presentation, Nov 26, 2018
Slide 1: PDS Biotechnology and Edge Therapeutics Proposed Combination
PDS Biotechnology and Edge TherapeuticsProposed Combination November 26, 2018 A new generation of multi-functional immunotherapies
Slide 2: Forward-Looking Statements
Forward-Looking Statements 1 This presentation contains forward-looking statements about Edge Therapeutics, Inc. and PDS Biotechnology Corporation, and their respective businesses, business prospects, strategy and plans, including but not limited to statements regarding anticipated preclinical and c
Slide 3: Other Important Information
Other Important Information 1 In connection with the proposed strategic merger, Edge intends to file relevant materials with the Securities and Exchange Commission (SEC), including a registration statement on Form S-4 that will contain a proxy statement and prospectus. Investors may obtain the proxy
Slide 4: Transaction Overview
Transaction Overview 1 Key Terms Board of Directors and Organization Timing and Closing Privately-held PDS Biotechnology has agreed to merge with a subsidiary of Edge Therapeutics in an all-stock transactionEdge shareholders expected to own ~30% of the combined company and PDS shareholders ~70%Upon
Slide 5: Edge and PDS Combined Company Overview
Edge and PDS Combined Company Overview 1 Proposed merger to form a clinical-stage cancer immunotherapy biotechnology company developing novel products for treating early- and late-stage cancerGrowing product pipeline utilizing Versamune®, a novel, versatile, multi-functional immunotherapy platform P
Slide 6: Versamune Has Potential to Address Key Immuno-oncology Limitations
1 Versamune® Has Potential to AddressKey Immuno-oncology Limitations Checkpoint Inhibitors CAR T-cells Cancer Vaccines Versamune® Induction of CD8+ (killer) T-cells X ✓Ex-vivo X ✓In-vivo Target tumor’s immune suppressive mechanisms ✓ X X ✓ Induction of memory T-cells X X ✓Predominantly CD4+ ✓ System
Slide 7: Versamune Unique Multiple Mechanisms of Action Promote In-vivo Killer T-cell Induction
Versamune ® Unique Multiple Mechanisms of Action Promote In-vivo Killer T-cell Induction Priming and training of tumor-recognizing killer T-cells (CD8+) Overcomes tumor immune suppression (Reduction of Tregs) Versamune SC Injection Activates critical immune signaling pathway to arm killer T-cells (T
Slide 8: PDS0101 Phase 1/2a Dose Escalation Study Supports Dose for Future Studies
PDS0101 Phase 1/2a Dose Escalation Study Supports 3 mg Dose for Future Studies 1 CD8+ T-Cells: Granzyme-b ELISPOT on Days 14-19 Post Treatment N=6 N=3 N=3 Open-label study to evaluate safety, tolerability and pharmacodynamics of PDS0101 in subjects withCervical Intraepithelial Neoplasia (CIN) and hi
Slide 9: Growing Pipeline of PDS Fully-Owned Cancer Immunotherapies
Growing Pipeline of PDS Fully-Owned Cancer Immunotherapies 1 Product Cancer Indication Preclinical Phase 1 Phase 2a Phase 2b PDS0101(HPV- related Cancers) Head & neck Recurrent/metastatic + pembrolizumab Cervical pre-cancer CIN 2/3 Anal pre-cancerAIN 2/3 Cervical Stage II-IVa PDS0102 Prostate and br
Slide 10: Versamune Competitive Barriers
Versamune ® Competitive Barriers Patent Protection in U.S., EU, Asia Patent Protection in U.S., EU, Asia Multiple issued patents: Expected to provide patent protection into the 2030s Multiple patent applications: Future patent applications could extend into the late-2030s Regulatory Exclusivity (Bio
Slide 11: PDS0101 Targets Large and Unmet Market Opportunities
PDS0101 Targets Large and Unmet Market Opportunities 1 HPV disease market is estimated to be over $5B worldwide by 2025HPV-Related CancersOver 75,000 new cases of HPV-related cancers in US and Europe annuallyHPV Pre-cancersOver 1million new incidences of high-grade, treatment-required HPV pre-cancer
Slide 12: Anticipated Milestones
1 Anticipated Milestones Initiate PDS0101 monotherapy registration program in Cervical Intraepithelial Neoplasia (CIN) 2/3Initiate PDS0101-Keytruda combination Phase 2 study in head and neck cancerComplete manufacturing of clinical supply for PDS0101Continue to advance prostate, ovarian and melanoma
Slide 13: Experienced Leadership Team
Experienced Leadership Team Frank Bedu-Addo, PhDCEO & Co-Founder Brian LeuthnerPresident Lauren Wood, MDChief Medical Officer Gregory Conn, PhDChief Scientific Officer & Co-Founder Andrew Saik, MBAChief Financial Officer NIH National Cancer Inst. 13
Slide 14: Board of Directors
Board of Directors Affiliation Frank Bedu-Addo, PhDCEO and Director CEO Brian LeuthnerPresident and Director CEO De Lyle Bloomquist Former Global President Gregory Freitag General Counsel, SVP of BD, BoD Sir Richard Sykes, PhD Former CEO James J. Loughlin Former Partner Robert Spiegel, M.D., FACP Fo
Slide 15: Edge and PDS Combined Company Overview
Edge and PDS Combined Company Overview 1 Proposed merger to form a clinical-stage cancer immunotherapy biotechnology company developing novel products for treating early- and late-stage cancerGrowing product pipeline utilizing Versamune®, a novel, versatile, multi-functional immunotherapy platform P
Edge Therapeutics — Merger or Acquisition (November 2018) on 6ix